Life Sciences Regenerative Therapy Platforms sector
Strategic acquirers, private equity (buyout funds and growth funds) firms, and valuation benchmarks for Life Sciences Regenerative Therapy Platforms
1.1 - About Life Sciences Regenerative Therapy Platforms sector
Companies in this category develop and manufacture cell-based and tissue-engineered therapeutics, along with enabling infrastructure that brings regenerative medicine to the clinic. Vendors in Life Sciences Regenerative Therapy Platforms provide stem cell and gene-modified products, biomaterials, and development services that restore or replace damaged tissues. They deliver translational expertise, GMP processes, and clinical support to move programs from discovery through approval, reducing risk and accelerating time to patient.
Offerings typically include autologous and allogeneic cell therapies, gene-editing and vector delivery platforms, and tissue engineering tools such as bioactive scaffolds and 3D bioprinting systems used to fabricate implants. Providers also supply cell culture media, closed bioreactor systems, and GMP-compliant manufacturing services with cryopreservation and cold-chain logistics. Many add potency assays, release testing, and clinical trial support, enabling scale-up, comparability, and regulatory-ready documentation across advanced therapy programs.
Primary customers include biopharma and biotech R&D organizations, hospital and specialty care providers, and academic medical centers or CDMOs supporting advanced therapies. These companies help buyers accelerate preclinical-to-clinical timelines, improve manufacturing yields and consistency, lower cost of goods, and strengthen regulatory readiness. Outcomes often include faster IND/IMPD filings, reduced batch failure rates, and improved clinical efficacy in indications such as orthopedics, cardiology, dermatology, and rare genetic disorders.
2. Buyers in the Life Sciences Regenerative Therapy Platforms sector
2.1 Top strategic acquirers of Life Sciences Regenerative Therapy Platforms companies
Humacyte
- Description: Provider of regenerative medicine solutions developing and manufacturing universally implantable, lab-grown acellular tissue engineered vessels (ATEV) and other bioengineered tissues that remodel with patients’ own cells to treat extremity arterial trauma, enable arteriovenous access for hemodialysis, address peripheral arterial disease and lay groundwork for future organ replacement applications.
- Key Products:
- Symvess (Acellular Tissue Engineered Vessel): FDA-approved, universally implantable bioengineered human vessel for extremity arterial trauma, provides off-the-shelf conduit when autologous vein grafts are infeasible and remodels with patient cells
- ATEV for Arteriovenous (AV) Access: Lab-grown vessel in clinical trials to create durable, infection-resistant access sites for hemodialysis patients, aiming to improve longevity over synthetic grafts
- ATEV for Peripheral Arterial Disease: Investigational vessel intended to restore blood flow in diseased peripheral arteries, offering biologically compatible alternative to synthetic bypass grafts
- Pipeline Tissue & Organ Applications: Preclinical programs exploring ATEV technology for coronary artery bypass, pediatric heart surgery and type-1 diabetes treatments, extending platform to multiple novel cell and tissue uses.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
2.2 - Strategic buyer groups for Life Sciences Regenerative Therapy Platforms sector
M&A buyer group 1: Cell Therapy
Precigen
- Type: N/A
- Employees: ●●●●●
- Description: Provider of biotechnology solutions focused on human gene therapy and gene editing, leveraging proprietary DNA-engineering technologies to control cellular functions and develop treatments such as CAR-T therapies for acute myeloid leukemia.
- Key Products:
- PRGN-3006 CAR-T Therapy: Investigational CAR-T treatment granted orphan drug status targeting acute myeloid leukemia by genetically engineering patient T-cells to attack cancer cells and potentially improve clinical outcomes
- Proprietary DNA Engineering Platform: Suite of complementary technologies that enables precise DNA-based control over cellular functions, supporting creation of diverse gene and cell therapies
- Human Gene Editing Programs: Focused research initiatives applying advanced gene-editing techniques to develop next-generation therapeutics for multiple diseases using Precigen’s engineered cell and gene platforms
Buyer group 2: ████████ ████████
●● companiesBuyer group 3: ████████ ████████
●● companies3. Investors and private equity firms in Life Sciences Regenerative Therapy Platforms sector
3.1 - Buyout funds in the Life Sciences Regenerative Therapy Platforms sector
2.2 - Strategic buyer groups for Life Sciences Regenerative Therapy Platforms sector
4 - Top valuation comps for Life Sciences Regenerative Therapy Platforms companies
4.2 - Public trading comparable groups for Life Sciences Regenerative Therapy Platforms sector
Valuation benchmark group 1: Cell and Gene Therapy Biopharma Companies
Novartis
- Enterprise value: $●●●m
- Market Cap: $●●●m
- EV/Revenue: ●.●x
- EV/EBITDA: ●●.●x
- Description: Provider of innovative medicines and treatments, focusing on the research, development, manufacturing, and marketing of patented pharmaceuticals in areas such as oncology, immunology, cardiovascular, ophthalmology, and neuroscience to improve and extend lives worldwide.
- Key Products:
- Oncology Treatments: Medications for various types of cancer
- Immunology Drugs: Treatments for autoimmune and inflammatory diseases
- Cardiovascular Medicines: Drugs for heart and vascular conditions
- Neuroscience Therapies: Pharmaceuticals for neurological and psychiatric disorders
- Ophthalmology Solutions: Treatments for eye diseases and conditions